- Home
- WU vs HCM Comparison
WU vs HCM Comparison
Compare WU & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WU
- HCM
- Stock Information
- Founded
- WU 1851
- HCM 2000
- Country
- WU United States
- HCM Hong Kong
- Employees
- WU N/A
- HCM N/A
- Industry
- WU Business Services
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- WU Consumer Discretionary
- HCM Health Care
- Exchange
- WU Nasdaq
- HCM Nasdaq
- Market Cap
- WU 3.3B
- HCM 2.5B
- IPO Year
- WU 2006
- HCM N/A
- Fundamental
- Price
- WU $9.76
- HCM $14.21
- Analyst Decision
- WU Hold
- HCM Hold
- Analyst Count
- WU 10
- HCM 1
- Target Price
- WU $11.19
- HCM $19.00
- AVG Volume (30 Days)
- WU 7.2M
- HCM 82.7K
- Earning Date
- WU 04-23-2025
- HCM 03-19-2025
- Dividend Yield
- WU 9.64%
- HCM N/A
- EPS Growth
- WU 59.38
- HCM N/A
- EPS
- WU 2.70
- HCM 0.04
- Revenue
- WU $4,144,200,000.00
- HCM $630,201,000.00
- Revenue This Year
- WU $1.48
- HCM $14.86
- Revenue Next Year
- WU $1.69
- HCM $19.54
- P/E Ratio
- WU $3.62
- HCM $68.70
- Revenue Growth
- WU N/A
- HCM N/A
- 52 Week Low
- WU $9.00
- HCM $11.51
- 52 Week High
- WU $13.49
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- WU 44.85
- HCM 45.83
- Support Level
- WU $9.63
- HCM $14.18
- Resistance Level
- WU $9.85
- HCM $14.84
- Average True Range (ATR)
- WU 0.27
- HCM 0.57
- MACD
- WU 0.00
- HCM -0.03
- Stochastic Oscillator
- WU 27.26
- HCM 1.94
About WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2024 and is the largest money transfer company in the world.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.